Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study

AIMS: Cardiac microRNA-132-3p (miR-132) levels are increased in patients with heart failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor that attenuates and even reverses HF in preclinical models. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Täubel, Jörg, Hauke, Wilfried, Rump, Steffen, Viereck, Janika, Batkai, Sandor, Poetzsch, Jenny, Rode, Laura, Weigt, Henning, Genschel, Celina, Lorch, Ulrike, Theek, Carmen, Levin, Arthur A, Bauersachs, Johann, Solomon, Scott D, Thum, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954267/
https://www.ncbi.nlm.nih.gov/pubmed/33245749
http://dx.doi.org/10.1093/eurheartj/ehaa898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954267/
https://www.ncbi.nlm.nih.gov/pubmed/33245749
http://dx.doi.org/10.1093/eurheartj/ehaa898

Ejemplares similares